Cramer knew well in advance that 2023 was likely to be a challenging year: It had worked on Aubagio, Sanofi’s blockbuster MS treatment, since 2015, and the drug was slated to lose its exclusivity in 2023. But the firm rallied in the year’s second half, winning patient support services assignments for Sanofi’s CareConnectPSS and Dupixent My Way programs. Cramer also added work on Albireo’s Bylvay — the only product that treats progressive familial intrahepatic cholestasis (PFIC) — to a roster that already included engagements with Quest Diagnostics, Becton Dickinson and Boston Scientific. The ledger might show a decline, but Cramer did a fine job setting itself up for growth in 2024 and beyond.
. . .
